JP2017537627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537627A5 JP2017537627A5 JP2017529682A JP2017529682A JP2017537627A5 JP 2017537627 A5 JP2017537627 A5 JP 2017537627A5 JP 2017529682 A JP2017529682 A JP 2017529682A JP 2017529682 A JP2017529682 A JP 2017529682A JP 2017537627 A5 JP2017537627 A5 JP 2017537627A5
- Authority
- JP
- Japan
- Prior art keywords
- signaling domain
- antigen receptor
- chimeric antigen
- domain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011664 signaling Effects 0.000 claims 50
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 125000006850 spacer group Chemical group 0.000 claims 22
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 20
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 20
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022001433A JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088423P | 2014-12-05 | 2014-12-05 | |
| US62/088,423 | 2014-12-05 | ||
| PCT/US2015/064303 WO2016090369A1 (en) | 2014-12-05 | 2015-12-07 | Cs1 targeted chimeric antigen receptor-modified t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022001433A Division JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537627A JP2017537627A (ja) | 2017-12-21 |
| JP2017537627A5 true JP2017537627A5 (cg-RX-API-DMAC7.html) | 2019-01-17 |
| JP7098325B2 JP7098325B2 (ja) | 2022-07-11 |
Family
ID=55069093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529682A Active JP7098325B2 (ja) | 2014-12-05 | 2015-12-07 | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| JP2022001433A Active JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022001433A Active JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10821161B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3227315B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7098325B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102558502B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107429253B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015357485B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017011893A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2969704C (cg-RX-API-DMAC7.html) |
| IL (3) | IL290459B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX384964B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2727451C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016090369A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| JP7098325B2 (ja) | 2014-12-05 | 2022-07-11 | シティ・オブ・ホープ | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| CA2973529A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| CN108350462B (zh) | 2015-09-11 | 2022-05-27 | 生物权威（英国）有限公司 | 嵌合抗原受体及其用途 |
| EP3408297A2 (en) | 2016-01-29 | 2018-12-05 | Med Manor Organics, (P) Ltd | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
| PE20190356A1 (es) | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| AU2017240150C1 (en) | 2016-04-01 | 2022-10-27 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| MX2018015414A (es) * | 2016-06-30 | 2019-08-01 | Hoffmann La Roche | Terapia de célula t adoptiva mejorada. |
| CN105949324B (zh) * | 2016-06-30 | 2019-08-27 | 上海恒润达生生物科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
| EP3518944A4 (en) * | 2016-09-30 | 2020-06-17 | Baylor College of Medicine | ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN |
| US12083148B2 (en) | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US20180280437A1 (en) | 2017-03-13 | 2018-10-04 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| JP2020511498A (ja) * | 2017-03-20 | 2020-04-16 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | Ａｌアミロイドーシスの治療のためのｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| ES3010117T3 (en) | 2017-03-27 | 2025-04-01 | Hoffmann La Roche | Improved antigen binding receptors |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| CA3061546C (en) | 2017-04-28 | 2023-09-19 | Julius-Maximilians-Universitat Wurzburg | Ror1-specific chimeric antigen receptors (car) with humanized targeting domains |
| EP3661511A1 (en) * | 2017-08-01 | 2020-06-10 | Julius-Maximilians-Universität Würzburg | Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia |
| CN111034336B (zh) | 2017-08-11 | 2024-04-09 | 交互数字专利控股公司 | 多个接入网络之间的业务引导和切换 |
| DK3704230T3 (da) * | 2017-11-01 | 2025-01-02 | Juno Therapeutics Inc | Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| IL274652B2 (en) * | 2017-11-14 | 2025-08-01 | Arcellx Inc | D-domain containing polypeptides and uses thereof |
| US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | Car t细胞的使用方法 |
| WO2019161271A1 (en) | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| US20220089718A1 (en) * | 2018-05-21 | 2022-03-24 | Biosceptre (Uk) Limited | Chimeric antigen receptors with modified linker domains and uses thereof |
| WO2020009868A1 (en) * | 2018-07-03 | 2020-01-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-slamf7 chimeric antigen receptors |
| EP3830133A1 (en) | 2018-08-01 | 2021-06-09 | City of Hope | Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors |
| WO2020025039A1 (zh) * | 2018-08-03 | 2020-02-06 | 南京驯鹿医疗技术有限公司 | 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用 |
| JP7386382B2 (ja) | 2018-12-12 | 2023-11-27 | カイト ファーマ インコーポレイテッド | キメラ抗原受容体及びｔ細胞受容体並びに使用方法 |
| KR20240122580A (ko) | 2019-04-03 | 2024-08-12 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
| US20220249560A1 (en) * | 2019-05-24 | 2022-08-11 | City Of Hope | Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies |
| CA3143108A1 (en) * | 2019-06-19 | 2020-12-24 | Julius-Maximilians-Universitat Wurzburg | Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| KR20230010228A (ko) * | 2020-05-08 | 2023-01-18 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars) |
| EP4158030A4 (en) * | 2020-05-27 | 2024-06-26 | The Medical College of Wisconsin, Inc. | Improved lentiviral vector transfer plasmid and methods of use |
| CN114286691B (zh) * | 2020-08-06 | 2024-08-06 | 武汉思安医疗技术有限公司 | Cs1-抗体和抗cs1-car-t细胞 |
| WO2022034022A1 (en) * | 2020-08-10 | 2022-02-17 | Julius-Maximilians-Universität Würzburg | Siglec-6-binding polypeptides |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022206941A1 (zh) * | 2021-04-02 | 2022-10-06 | 克莱格医学有限公司 | Cs1工程化细胞及其组合物 |
| WO2023107898A1 (en) * | 2021-12-06 | 2023-06-15 | The Children's Hospital Of Philadelphia | Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices) |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| EP4499230A1 (en) * | 2022-03-25 | 2025-02-05 | F. Hoffmann-La Roche AG | Improved chimeric receptors |
| CN120344563A (zh) * | 2022-12-02 | 2025-07-18 | 广州荔泰生物科技有限公司 | 人cs1 car-t细胞 |
| CN119019554B (zh) * | 2023-05-25 | 2025-08-12 | 东莞市朋志生物科技有限公司 | 抗白介素6抗体、检测白介素6的试剂和试剂盒 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2064814C (en) | 1989-08-11 | 2004-06-08 | Nicos Anthony Nicola | Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| WO2007047829A2 (en) | 2005-10-19 | 2007-04-26 | Laboratoires Serono S.A. | Novel heterodimeric proteins and uses thereof |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| JP6034696B2 (ja) | 2010-02-12 | 2016-11-30 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ポリペプチド発現細胞の同定及び単離の方法 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| KR102132041B1 (ko) | 2012-04-05 | 2020-07-09 | 에이씨 이뮨 에스.에이. | 인간화된 타우 항체 |
| WO2014179759A1 (en) * | 2013-05-03 | 2014-11-06 | Ohio State Innovation Foundation | Cs1-specific chimeric antigen receptor engineered immune effector cells |
| EP3626748A1 (en) * | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| KR102157924B1 (ko) * | 2014-02-14 | 2020-10-26 | 셀렉티스 | 면역 세포들 및 병리 세포들 둘 다에 존재하는 항원을 타겟팅하기 위하여 조작된 면역치료용 세포들 |
| EP3137498A1 (en) * | 2014-05-02 | 2017-03-08 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| JP7098325B2 (ja) | 2014-12-05 | 2022-07-11 | シティ・オブ・ホープ | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| JP2020511498A (ja) * | 2017-03-20 | 2020-04-16 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | Ａｌアミロイドーシスの治療のためのｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
-
2015
- 2015-12-07 JP JP2017529682A patent/JP7098325B2/ja active Active
- 2015-12-07 US US15/533,153 patent/US10821161B2/en active Active
- 2015-12-07 MX MX2017007250A patent/MX384964B/es unknown
- 2015-12-07 CN CN201580075401.6A patent/CN107429253B/zh not_active Expired - Fee Related
- 2015-12-07 CN CN202111214014.XA patent/CN114085856A/zh active Pending
- 2015-12-07 CA CA2969704A patent/CA2969704C/en active Active
- 2015-12-07 WO PCT/US2015/064303 patent/WO2016090369A1/en not_active Ceased
- 2015-12-07 BR BR112017011893-9A patent/BR112017011893A2/pt not_active Application Discontinuation
- 2015-12-07 EP EP15819937.2A patent/EP3227315B1/en not_active Not-in-force
- 2015-12-07 EP EP22208847.8A patent/EP4219530A1/en not_active Withdrawn
- 2015-12-07 AU AU2015357485A patent/AU2015357485B2/en not_active Ceased
- 2015-12-07 KR KR1020177018597A patent/KR102558502B1/ko active Active
- 2015-12-07 RU RU2017121826A patent/RU2727451C2/ru active
- 2015-12-07 IL IL290459A patent/IL290459B2/en unknown
-
2017
- 2017-06-04 IL IL252645A patent/IL252645B/en active IP Right Grant
- 2017-06-05 MX MX2021008498A patent/MX2021008498A/es unknown
-
2020
- 2020-08-13 US US16/992,361 patent/US11730797B2/en active Active
-
2021
- 2021-01-11 AU AU2021200122A patent/AU2021200122B2/en not_active Ceased
- 2021-02-16 IL IL280917A patent/IL280917B/en unknown
-
2022
- 2022-01-07 JP JP2022001433A patent/JP7252379B2/ja active Active
-
2023
- 2023-07-10 US US18/349,678 patent/US12497440B2/en active Active